{"id":449177,"date":"2021-03-03T03:52:31","date_gmt":"2021-03-03T08:52:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=449177"},"modified":"2021-03-03T03:52:31","modified_gmt":"2021-03-03T08:52:31","slug":"shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/","title":{"rendered":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. – BCLI"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, March 3, 2021<\/span> \/PRNewswire\/ —\u00a0Pomerantz LLP is investigating claims on behalf of investors of\u00a0Brainstorm Cell Therapeutics Inc.\u00a0(“Brainstorm” or the “Company”)\u00a0(NASDAQ:\u00a0 BCLI).\u00a0 Such investors are advised to contact Robert S. Willoughby<\/span> at rswilloughby@pomlaw.com<\/a>\u00a0or 888-476-6529, ext. 9980.<\/p>\n

The investigation concerns whether Brainstorm and certain of its officers and\/or directors have engaged in securities fraud or other unlawful business practices.\u00a0 <\/p>\n

\n
\n [Click here for information about joining the class action]<\/b>
\n <\/a>\u00a0<\/p>\n

On February 22, 2021<\/span>, Brainstorm issued a press release “announc[ing] . . . that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. \u00a0The FDA concluded from their initial review that the current level of clinical data does not provide the threshold of substantial evidence that FDA is seeking to support a\u00a0Biologics License Application (BLA).”\u00a0 The press release quoted Brainstorm’s Chief Executive Officer, Chaim Lebovits<\/span>, as stating that “Brainstorm will first\u00a0consult with principal investigators, ALS experts, expert statisticians, regulatory advisors, and ALS advocacy groups to assess the benefit\/risk of a BLA submission before making a final decision[.]”\u00a0 <\/p>\n

On this news, Brainstorm’s stock price fell $2.32<\/span> or 33.62% to close at $4.58<\/span> per share on February 22, 2021<\/span>.<\/p>\n

The Pomerantz Firm, with offices in New York<\/span>, Chicago<\/span>, Los Angeles<\/span>, and Paris<\/span> is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz<\/span>, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com<\/a><\/p>\n

\n CONTACT:
<\/b>
\n Robert S. Willoughby<\/span>
\n
Pomerantz LLP
rswilloughby@pomlaw.com<\/a>
888-476-6529 ext. 7980<\/p>\n

\u00a0<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc—bcli-301239286.html<\/a><\/p>\n

SOURCE Pomerantz LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, March 3, 2021 \/PRNewswire\/ —\u00a0Pomerantz LLP is investigating claims on behalf of investors of\u00a0Brainstorm Cell Therapeutics Inc.\u00a0(“Brainstorm” or the “Company”)\u00a0(NASDAQ:\u00a0 BCLI).\u00a0 Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com\u00a0or 888-476-6529, ext. 9980. The investigation concerns whether Brainstorm and certain of its officers and\/or directors have engaged in securities fraud or other unlawful business practices.\u00a0 [Click here for information about joining the class action] \u00a0 On February 22, 2021, Brainstorm issued a press release “announc[ing] . . . that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. \u00a0The … <\/p>\n

Continue reading “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. – BCLI”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-449177","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, March 3, 2021 \/PRNewswire\/ —\u00a0Pomerantz LLP is investigating claims on behalf of investors of\u00a0Brainstorm Cell Therapeutics Inc.\u00a0(“Brainstorm” or the “Company”)\u00a0(NASDAQ:\u00a0 BCLI).\u00a0 Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com\u00a0or 888-476-6529, ext. 9980. The investigation concerns whether Brainstorm and certain of its officers and\/or directors have engaged in securities fraud or other unlawful business practices.\u00a0 [Click here for information about joining the class action] \u00a0 On February 22, 2021, Brainstorm issued a press release “announc[ing] . . . that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. \u00a0The … Continue reading "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. – BCLI"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T08:52:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC97281&sd=2021-03-03\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. – BCLI\",\"datePublished\":\"2021-03-03T08:52:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/\"},\"wordCount\":360,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC97281&sd=2021-03-03\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/\",\"name\":\"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC97281&sd=2021-03-03\",\"datePublished\":\"2021-03-03T08:52:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC97281&sd=2021-03-03\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=DC97281&sd=2021-03-03\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. – BCLI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI - Market Newsdesk","og_description":"PR Newswire NEW YORK, March 3, 2021 \/PRNewswire\/ —\u00a0Pomerantz LLP is investigating claims on behalf of investors of\u00a0Brainstorm Cell Therapeutics Inc.\u00a0(“Brainstorm” or the “Company”)\u00a0(NASDAQ:\u00a0 BCLI).\u00a0 Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com\u00a0or 888-476-6529, ext. 9980. The investigation concerns whether Brainstorm and certain of its officers and\/or directors have engaged in securities fraud or other unlawful business practices.\u00a0 [Click here for information about joining the class action] \u00a0 On February 22, 2021, Brainstorm issued a press release “announc[ing] . . . that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA feedback on a high-level data summary from the NurOwn (autologous MSC-NTF cells) ALS Phase 3 clinical trial. \u00a0The … Continue reading \"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. – BCLI\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-03T08:52:31+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC97281&sd=2021-03-03","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. – BCLI","datePublished":"2021-03-03T08:52:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/"},"wordCount":360,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC97281&sd=2021-03-03","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/","name":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC97281&sd=2021-03-03","datePublished":"2021-03-03T08:52:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC97281&sd=2021-03-03","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC97281&sd=2021-03-03"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-brainstorm-cell-therapeutics-inc-bcli-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. – BCLI"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=449177"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449177\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=449177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=449177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=449177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}